US FDA's Medtech Compliance Office Looks Ahead To 2016
This article was originally published in SRA
The Office of Compliance at the US Food and Drug Administration's device center will put greater emphasis on informal interactions with companies for minor compliance issues, according to Sean Boyd, acting director of the office.
You may also be interested in...
Despite seeing an 8% drop in global turnover in 2019, an upbeat Teva says the completion of its restructuring plan has positioned the company to increase its turnover through newly-launched products – including biosimilars, brands and new generics – as well as improve its profit margins through manufacturing optimization.
Japanese big pharma Eisai taps Celgene and Sanofi execs as its new VPs for corporate affairs and market access. And Freeline Therapeutics, developer of gene therapies for bleeding disorders, selects a former Alnylam Pharma SVP as CEO.